Navigation Links
Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Radiation Therapy
Date:2/3/2008

CALGARY, Feb. 4 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ('Oncolytics') reported today that Dr. Kevin Harrington and his research group at The Institute of Cancer Research, London, U.K. published the results of their work testing combination treatment schedules of reovirus and radiation in human and murine tumour cells in vitro and in vivo. The paper, entitled "Enhanced In vitro and In vivo Cytotoxicity of Combined Reovirus and Radiotherapy" appears online in the February 1, 2008 issue of Clinical Cancer Research.

The effect of different schedules of reovirus and radiotherapy on viral replication and cytotoxicity was tested in vitro and the combination was assessed in three tumour models in vivo. The results demonstrated that combining reovirus and radiotherapy significantly increased cancer cell killing both in vitro and in vivo, particularly in cell lines with moderate susceptibility to reovirus alone.

"Dr. Harrington's work demonstrates convincingly that REOLYSIN(R) works to enhance the effects of radiation therapy," said Dr. Matt Coffey, Chief Scientific Officer of Oncolytics. "The results of this preclinical research provided strong support for the combination REOLYSIN(R) and radiation clinical trials we are conducting in the U.K. To date, we have successfully completed enrolment in a Phase Ia/Ib combination REOLYSIN(R) and radiation trial and are currently enrolling patients in a Phase II trial using this combination."

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... September 23, 2014 Erlab , ... personnel since 1968 and Burdinola, supplier of laboratory furniture ... new filtered fume hood. , By integrating ... hood, Burdinola will now offer an innovative solution utilizing ... range of chemicals, best-in-class detection technology, and communication for ...
(Date:9/23/2014)... , Sept. 23, 2014 ... the "Proteomics Markets for Research and IVD ... Technologies)" report to their offering. ... for proteomics applications, both in their research use ... proteins, including the study of the structure and ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 For the fifth ... Inc. 500|5000 list of the fastest-growing companies. , “We’re ... acknowledged yet again by Inc. Magazine,” ExakTime CEO Tony Pappas ... list by posting a three-year growth rate of 61 percent ... that time by more than 40 percent. , Pappas cited ...
(Date:9/23/2014)... 23, 2014 Follow us ... steady popularity the world over, due to its ... in the marketplace is expected to come from ... developing countries. Several sub-Saharan countries in the African ... already implemented genetically engineered crop production strategies. Rising ...
Breaking Biology Technology:Erlab Partners with Burdinola to Deliver an Innovative Filtered Fume Hood 2Proteomics Markets for Research and IVD Applications (Mass Spectrometry, Chromatography, Microarrays, Electrophoresis, Immunoassays, Other Technologies) 2Proteomics Markets for Research and IVD Applications (Mass Spectrometry, Chromatography, Microarrays, Electrophoresis, Immunoassays, Other Technologies) 3Proteomics Markets for Research and IVD Applications (Mass Spectrometry, Chromatography, Microarrays, Electrophoresis, Immunoassays, Other Technologies) 4ExakTime Makes Inc. 5000 List for the Fifth Time 2Rising Focus on Food Security Spurs Growth in the Global Agricultural Biotechnology Market, According to New Report by Global Industry Analysts, Inc. 2Rising Focus on Food Security Spurs Growth in the Global Agricultural Biotechnology Market, According to New Report by Global Industry Analysts, Inc. 3Rising Focus on Food Security Spurs Growth in the Global Agricultural Biotechnology Market, According to New Report by Global Industry Analysts, Inc. 4
... , SILVER SPRING, Md. , Feb. ... announced today that it will release its fourth quarter and ... February 16, 2010 . , United Therapeutics will host a ... 9:00 a.m. Eastern Time .  The teleconference is accessible ...
... Ind. , Feb. 9 The American Psychiatric Association ... to prepare and manage all industry-supported symposia (ISS) programming at its ... 22-26, 2010 . , CME Enterprise will manage all elements ... partnership with the APA. , "It is a tremendous honor ...
... , , , , , , LEUVEN, ... - Paper Examines the Potential of Microplasmin to Improve the Treatment,of ... ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company,focused on the discovery ... today that the positive,microplasmin Phase II trial results, evaluating the product,s efficacy ...
Cached Biology Technology:CME Enterprise Named to Manage All Industry-Supported Symposia at 2010 APA Annual Meeting 2ThromboGenics - Positive Microplasmin Phase II Data Published in Ophthalmology 2ThromboGenics - Positive Microplasmin Phase II Data Published in Ophthalmology 3ThromboGenics - Positive Microplasmin Phase II Data Published in Ophthalmology 4
(Date:9/23/2014)... The successful rise and fall of an athlete,s moving body ... tendons, putting the many angles and intersecting planes literally ... joint to the test. But it,s more than just a ... devastating of sports injuries: the ACL or anterior cruciate ligament ... sits at the center of the knee joint and ...
(Date:9/23/2014)... A multidisciplinary team at the University of Wisconsin-Madison and ... more affordable way to screen for neural toxins, helping ... National Institutes of Health (NIH) announced today that the ... support to continue the promising work as part of ... will receive approximately $7 million over the three-year project. ...
(Date:9/23/2014)... award funds to support the next phase of its ... of predicting drug safety and effectiveness. Researchers will collaborate ... chips and combine them into an integrated system that ... Led by the National Center for Advancing Translational Sciences ... million in 2014 with additional support over the remaining ...
Breaking Biology News(10 mins):Does size matter? MRI imaging sheds light on athletes most at risk for severe knee injury 2Does size matter? MRI imaging sheds light on athletes most at risk for severe knee injury 3UW-Madison team developing 'tissue chip' to screen neurological toxins 2UW-Madison team developing 'tissue chip' to screen neurological toxins 3NIH funds next phase of Tissue Chip for Drug Screening program 2NIH funds next phase of Tissue Chip for Drug Screening program 3NIH funds next phase of Tissue Chip for Drug Screening program 4
... just a single island in the remote South Pacific, is ... also one of the oldest flowering plants, having branched off ... Indiana University, with the U.S. Department of Energy Joint Genome ... Research for Development in New Caledonia, have determined a remarkable ...
... Ven, Department of Molecular Biology and Genetics and the ... microRNA-128 just published in Science . In the ... amount of microRNA-128 in specific neurons that react to ... in these neurons in neonatal mice, it results in ...
... a cloudless day in Dangriga, a coastal city in southern ... wall of their sun-strewn lab is lined with the usual ... tubes. Swathed in purple gloves, they measure samples, mix gels ... usual class this is not. It is part of ...
Cached Biology News:A gluttonous plant reveals how its cellular power plant devours foreign DNA 2A gluttonous plant reveals how its cellular power plant devours foreign DNA 3New research provides insight into epilepsy 2Beyond Mendel 2Beyond Mendel 3Beyond Mendel 4
The PROTEAN II slab gel casting stand is a component of the PROTEAN II XL and xi casting apparatus. It is supplied with gaskets....
... The Dyad Disciple thermal cycler is a ... may also be operated independently, using a ... of interchangeable Alpha units (sample-holder, heat-pump assemblies), ... as the Chromo4 real-time detector. Peltier heat ...
...
I-Ab MHC Class II...
Biology Products: